N/A N=38 Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology
Dystonia-Parkinsonism, Adult-Onset · Parkinson Disease
Primary: Burke-Fahn-Marsden Dystonia Rating Scale — 3.5 units on a scale — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=5 Thalamic Deep Brain Stimulation for Secondary Dystonia in Children and Young Adults
Dystonia
Primary: Change From Baseline in Burke-Fahn-Marsden Dystonia Rating Scale — 14.7 change in points on a scale
Phase 2 N=16 Amlodipine Plus Botulinum Toxin for Focal Dystonia
Focal Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTR) Sum Score — -6.00; -3.23 units on a scale
N/A N=9 Deep Brain Stimulation in Patients With Dystonia
Dystonia
Primary: The Toronto Western Spasmodic Rating Scale (TWSTRS) Movement Scores Measured Before DBS Surgery (Baseline) and at 12 Months — 33.5 TWSTRS total score change
N/A N=37 Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD
Parkinson's Disease
Primary: L-DOPA Insensitivity — 5 Participants — p=0.00468
N/A N=9 rTMS and Botulinum Toxin in Primary Cervical Dystonia
Primary Cervical Dystonia · Dystonia
Primary: Dystonia Severity as Assessed by the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — 13; 17 scores on a scale
Phase 3 N=63 A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
Cerebral Palsy, Dyskinetic
Primary: Change From Baseline in the Movement Disorder-Childhood Rating Scale (MD-CRS) Part II Total Score (Movement Disorder Severity, Centrally Read) at Week 15 — -0.4; -1.5…
Phase 2 N=253 Dyskinesia in Parkinson's Disease (Study P04501)
Parkinson Disease · Movement Disorders · Central Nervous System Diseases
Primary: Change From Baseline to Endpoint of 12 Weeks in the 3-day Average of Awake Time Per Day Spent in the "Off" State — -0.4; -1.3; -1.6; -1.7 hours/day — p=0.753
N/A N=8 Identification of Optimal Stimulation Site for Cervical Dystonia Symptoms: An Exploratory Study
Cervical Dystonia · Spasmodic Torticollis
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — -3.0; 0.25; -2.9; -1.5 units on a scale
Phase 2 N=15 An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsTonia
Dystonia, Primary
Primary: Proportion of Study Subjects Able to Titrate up to the Maximum Tolerated Dose — 6 Participants
N/A N=5 Dystonia Treatment With Injections Supplemented By Transcranial Magnetic Stimulation
Cervical Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — 17; 16.6; 17; 15.8 score on a scale — p=0.691
Phase 2 N=25 Transcranial Direct Current Stimulation to Treat Symptoms of Parkinson's Disease
Parkinson Disease
Primary: Gait Speed Before and After Real and Sham tDCS. — 8.7; 8.6; 9.7; 9.5 Seconds
Phase 3 N=506 Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
Parkinson's Disease · Dyskinesia
Primary: Responder Rate Based on Unified Parkinson's Disease Rating Scale (UPDRS) Items 32 and 33 at Week 12 — 30.4; 33.2 percentage of subjects
Phase 3 N=507 Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)
Parkinson Disease
Primary: Change From Baseline in the Total "On" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser…
Phase 2 N=7 Efficacy of Levetiracetam in Oromandibular and Cranial Dystonia
Oromandibular Dystonia · Cranial Dystonia
Primary: Percent Change of the Sum of the Eyes, Mouth, Speech and Swallowing Subscores of the Burke-Fahn-Marsden (BFM) Dystonia Scale. — 12.16; 31.25 percent change
Phase 2 N=75 Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia
Parkinson Disease
Primary: Unified Dyskinesia Rating Scale (UDysRS) — -4.2; -7.0 score on a scale
N/A N=12 Neuromodulation Therapy for Task-Specific Dystonia
Isolated Focal Hand Dystonia
Primary: Feasibility of Accurately Delivering TMS During the Task of Writing as Measured by Number of Participants Who Completed the TMS Sessions — 12; 12; 11 Participants
N/A N=42 Effect of Levodopa on Postural Motor Learning in Parkinson Disease
Parkinson Disease
Primary: Change in Movement of Center of Mass (COM) After Postural Perturbation — 0.31; 0.28; 0.32; 0.26 meters
Phase 3 N=298 Addressing Involuntary Movements in Tardive Dyskinesia
Tardive Dyskinesia
Primary: Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM) — -1.4; -2.1; -3.2; -3.3…
Phase 2 N=14 Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
Dyskinesia · Parkinson's Disease
Primary: Least Squares Mean Dyskinesia Severity Area Under the Curve (AUC) Score As Assessed By Modified Movement Disorder Society-Unified Dyskinesia Rating Scale (MDS-UDysRS)…
Phase 4 N=40 Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease
Parkinson's Disease
Primary: Unified Parkinson Disease Rating Scale (UPDRS). — 12; 12; 10; 10 units on a scale
N/A N=12 Repetitive Transcranial Magnetic Stimulation (rTMS) for Dystonia and Tremor
Dystonia · Tremor
Primary: Cognitive Assessment Using MoCA Version 7.1 Scores — 25.45; 27 units on a scale
Phase 2 N=16 Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease
Parkinson Disease
Primary: Change in the MDS-UPDRS Tremor Subscore — 0.25; 0.27 score on a scale — p=0.5
Phase 1 N=30 Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids
Parkinson's Disease
Primary: Efficacy of DHA - Change in Blood ng/dL Levels — 102.18; -13.20 ng/dL - Blood
N/A N=9 Bracing for Walking in Parkinson's Disease
Gait Disorders, Neurologic · Parkinson Disease
Primary: Change in Gait Capacity as Assessed b 6-Minute Walk Test — 235.7; 150.0 Feet
Phase 3 N=112 Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia
Cervical Dystonia
Primary: TWSTRS Total Score at Week 4 and Week 12 for Treatment Cycles 1, 2 and 3. — 37.7; 30.1; 32.6; 27.0 units on a scale
N/A N=6 Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial
Spasmodic Dysphonia · Laryngeal Dystonia · Deep Brain Stimulation
Primary: Unified Spasmodic Dysphonia Rating Scale (USDRS) — 2.5; 3.75 units on a scale — p=0.025
N/A N=7 Cerebellar Transcranial Direct Current Stimulation in Parkinson's Disease
Parkinson Disease · Brain Stimulation · Cerebellum
Primary: Speed Walked During 30 Meter Walk Test — 5.63; 5.65; 5.77; 5.86 meters per second (m/s)
N/A N=1,046 CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinumtoxinA Efficacy
Cervical Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score — 27.1 score on a scale
Phase 2 N=155 A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia
Parkinson Disease
Primary: Change in Average Daily Hours of ON-time Without Troublesome Dyskinesia With Mesdopetam Compared to Placebo as Assessed With 24-hour Patient Home Diaries From Baseline…